Additionally, it is essential to validate the involvement of these molecules in specific disease mechanisms while exploring their potential as therapeutic targets.Secondly, there are different dimensions of DVT, that is, different causes of DVT, and SIRT2 and CCL20 have different mutation genes. This evidence concerns the gene CCL20 and deep vein thrombosis.